Otsuka, Acucela JV Ready Phase III Trials Of Dry AMD Drug In Europe, U.S.
This article was originally published in PharmAsia News
Executive Summary
Otsuka Pharmaceutical is set to begin Phase III clinical trials in Europe and the United States with Acucela, a biotech begun by a Japanese ophthalmologist in the U.S. Otsuka is a major investor in the venture that has developed an orally delivered drug for the dry form of age-related macular degeneration.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.